The use of peptide-major-histocompatibility-complex multimers in type 1 diabetes mellitus

Journal of Diabetes Science and Technology

Volumn 6, Issue 3, 2012, Pages 515-524

  Gojanovich, Greg S ^a   Murray, Sabrina L ^a   Buntzman, Adam S ^b   Young, Ellen F ^c   Vincent, Benjamin G ^c   Hess, Paul R ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen specific T cells; Autoimmunity; Immunomodulation; Major histocompatibility complex; Multimers; Type 1 diabetes mellitus

Indexed keywords

ALLOANTIGEN; DOXORUBICIN; GAMMA INTERFERON; GLUCOSE 6 PHOSPHATASE; IMMUNOTOXIN; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 10; INTERLEUKIN 2; MAGNETIC NANOPARTICLE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PEPTIDE MAJOR HISTOCOMPATIBILITY COMPLEX MULTIMER; POLYMER; REAGENT; STREPTAVIDIN; TETRAMER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; HISTOCOMPATIBILITY ANTIGEN;

ALLERGIC REACTION; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; AUTOIMMUNE DISEASE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INVASION; CELL POPULATION; CELL SEPARATION; CELL SURFACE; CONFERENCE PAPER; COVALENT BOND; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DIABETOGENESIS; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NONHUMAN; PANCREAS ISLET CELL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; ANIMAL; AUTOIMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; METHODOLOGY; MOLECULAR IMAGING; PROTEIN MULTIMERIZATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR IMAGING; PEPTIDES; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84879709111     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600305     Document Type: Conference Paper

References (55)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
2. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289(17):2254-64. (Pubitemid 37430194)
3. Baiu D, Merriam F, Odorico J. Potential pathways to restore β-cell mass: pluripotent stem cells, reprogramming, and endogenous regeneration. Curr Diab Rep. 2011;11(5):392-401.
4. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B, Pipeleers D, Claas FH, de Vries RR. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes. 1999;48(3):484-90. (Pubitemid 29106860)
5. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A. 1994;91(1):123-7. (Pubitemid 24018655)
6. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol. 2010;6(3):149-57.
7. Keymeulen B, Candon S, Fafi-Kremer S, Ziegler A, Leruez-Ville M, Mathieu C, Vandemeulebroucke E, Walter M, Crenier L, Thervet E, Legendre C, Pierard D, Hale G, Waldmann H, Bach JF, Seigneurin JM, Pipeleers D, Chatenoud L. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood. 2010;115(6):1145-55.
8. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol. 2010;10(7):501-13.
9. Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol. 1993;23(12):3358-60. (Pubitemid 23353790)
10. Yagi H, Matsumoto M, Kunimoto K, Kawaguchi J, Makino S, Harada M. Analysis of the roles of CD4+ and CD8+ T cells in auto-immune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur J Immunol. 1992;22(9):2387-93.
11. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest. 1993;92(5):2313-22. (Pubitemid 23333537)
12. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest. 1985;53(2):132-44. (Pubitemid 15049005)
13. DiLorenzo TP, Graser RT, Ono T, Christianson GJ, Chapman HD, Roopenian DC, Nathenson SG, Serreze DV. Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc Natl Acad Sci U S A 1998;95(21):12538-43.
14. Wang J, Tsai S, Shameli A, Yamanouchi J, Alkemade G, Santamaria P. In situ recognition of autoantigen as an essential gatekeeper in autoimmune CD8+ T cell inflammation. Proc Natl Acad Sci U S A. 2010;107(20):9317-22.
15. Moriwaki M, Itoh N, Miyagawa J, Yamamoto K, Imagawa A, Yamagata K, Iwahashi H, Nakajima H, Namba M, Nagata S, Hanafusa T, Matsuzawa Y. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset type I diabetes mellitus. Diabetologia. 1999;42(11):1332-40. (Pubitemid 29500970)
16. Wong F, Visintin I, Wen L, Flavell R, Janeway JC. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med. 1996;183(1):67-76. (Pubitemid 26028746)
17. Prange S, Zucker P, Jevnikar AM, Singh B. Transplanted MHC class I-deficient nonobese diabetic mouse islets are protected from autoimmune injury in diabetic nonobese recipients. Transplantation. 2001;71(7):982-5. (Pubitemid 32417362)
18. Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, Kedl RM, Jenkins MK. Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity. 2007;27(2):203-13. (Pubitemid 47284919)
19. Obar JJ, Khanna KM, Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity. 2008;28(6):859-69.
20. Wang B, Maile R, Greenwood R, Collins EJ, Frelinger JA. Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells. J Immunol. 2000;164(3):1216-22. (Pubitemid 30067232)
21. Maile R, Pop SM, Tisch R, Collins EJ, Cairns BA, Frelinger JA. Low-avidity CD8lo T cells induced by incomplete antigen stimulation in vivo regulate naive higher avidity CD8hi T cell responses to the same antigen. Eur J Immunol 2006;36(2):397-410. (Pubitemid 43257463)
22. Samanta D, Mukherjee G, Ramagopal UA, Chaparro RJ, Nathenson SG, DiLorenzo TP, Almo SC. Structural and functional characterization of a single-chain peptide-MHC molecule that modulates both naive and activated CD8+ T cells. Proc Natl Acad Sci U S A. 2011;108(33):13682-7.
23. Cebecauer M, Guillaume P, Hozák P, Mark S, Everett H, Schneider P, Luescher IF. Soluble MHC-peptide complexes induce rapid death of CD8+ CTL. J Immunol. 2005;174(11):6809-19. (Pubitemid 40705644)
24. Yuan RR, Wong P, McDevitt MR, Doubrovina E, Leiner I, Bornmann W, O'reilly R, Pamer EG, Scheinberg DA. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood. 2004;104(8):2397-402. (Pubitemid 39331839)
25. Hess PR, Barnes C, Woolard MD, Johnson MD, Cullen JM, Collins EJ, Frelinger JA. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood. 2007;109(8):3300-7. (Pubitemid 46572517)
26. Clark BR, Deshpande SV, Sharma SD, Nag B. Antigen-specific deletion of cloned T cells using peptide-toxin conjugate complexed with purified class II major histocompatibility complex antigen. J Biol Chem. 1994;269(1):94-9. (Pubitemid 24026628)
27. Casares S, Stan AC, Bona CA, Brumeanu TD. Antigen-specific down-regulation of T cells by doxorubicin delivered through a recombinant MHC II - peptide chimera. Nat Biotechnol. 2001;19(2):142-7. (Pubitemid 32144442)
28. Toebes M, Rodenko B, Ovaa H, Schumacher TN. Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr Protoc Immunol. 2009;Chapter 18:Unit 18.16.
29. Ge Q, Stone JD, Thompson MT, Cochran JR, Rushe M, Eisen HN, Chen J, Stern LJ. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. Proc Natl Acad Sci U S A. 2002;99(21):13729-34. (Pubitemid 35215449)
30. Drake DR 3rd, Ream RM, Lawrence CW, Braciale TJ. Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function. J Immunol. 2005;175(3):1507-15. (Pubitemid 41023051)
31. Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, Santamaria P, Tan R. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest. 2003;111(2):217-23. (Pubitemid 36105920)
32. Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M, Bakker AH, Reker-Hadrup S, Keymeulen B, Drijfhout JW, Schumacher TN, Roep BO. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes. 2010;59(7):1721-30.
33. Unger WW, Velthuis J, Abreu JR, Laban S, Quinten E, Kester MG, Reker-Hadrup S, Bakker AH, Duinkerken G, Mulder A, Franken KL, Hilbrands R, Keymeulen B, Peakman M, Ossendorp F, Drijfhout JW, Schumacher TN, Roep BO. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun. 2011;37(3):151-9.
34. Moore A, Grimm J, Han B, Santamaria P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes. 2004;53(6):1459-66. (Pubitemid 38697657)
35. Medarova Z, Tsai S, Evgenov N, Santamaria P, Moore A. In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression. Magn Reson Med. 2008;59(4):712-20. (Pubitemid 351501935)
36. Liu CP, Jiang K, Wu CH, Lee WH, Lin WJ. Detection of glutamic acid decarboxylase-activated T cells with I-Ag7 tetramers. Proc Natl Acad Sci U S A. 2000;97(26):14596-601. (Pubitemid 32016621)
37. Reijonen H, Novak EJ, Kochik S, Heninger A, Liu AW, Kwok WW, Nepom GT. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes. 2002;51(5):1375-82. (Pubitemid 34826602)
38. Casares S, Hurtado A, McEvoy RC, Sarukhan A, von Boehmer H, Brumeanu TD. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol. 2002;3(4):383-91. (Pubitemid 34308627)
39. Preda-Pais A, Stan AC, Casares S, Bona C, Brumeanu TD. Efficacy of clonal deletion vs. anergy of self-reactive CD4 T-cells for the prevention and reversal of autoimmune diabetes. J Autoimmun. 2005;25(1):21-32. (Pubitemid 41008663)
40. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol. 2003;171(10):5587-95. (Pubitemid 37432850)
41. Li L, Yi Z, Wang B, Tisch R. Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination. J Immunol. 2009;183(7):4809-16.
42. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A. 1992;89(8):3429-33.
43. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274(5284):94-6. (Pubitemid 26332731)
44. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, Shastri N, Pamer EG, Janeway CA Jr. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med. 1999;5(9):1026-31. (Pubitemid 29439573)
45. Lieberman SM, Takaki T, Han B, Santamaria P, Serreze DV, DiLorenzo TP. Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol. 2004;173(11):6727-34. (Pubitemid 39541058)
46. Martinuzzi E, Novelli G, Scotto M, Blancou P, Bach JM, Chaillous L, Bruno G, Chatenoud L, van Endert P, Mallone R. The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes. 2008;57(5):1312-20.
47. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature. 2000;406(6797):739-42.
48. Han B, Serra P, Amrani A, Yamanouchi J, Marée AF, Edelstein-Keshet L, Santamaria P. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide. Nat Med. 2005;11(6):645-52. (Pubitemid 40868305)
49. O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. J Immunol. 2001;167(5):2555-60. (Pubitemid 32768882)
50. Maile R, Wang B, Schooler W, Meyer A, Collins EJ, Frelinger JA. Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J Immunol. 2001;167(7):3708-14. (Pubitemid 32910815)
51. Dal Porto J, Johansen TE, Catipović B, Parfiit DJ, Tuveson D, Gether U, Kozlowski S, Fearon DT, Schneck JP. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A. 1993;90(14):6671-5. (Pubitemid 23207275)
52. Angelov GS, Guillaume P, Cebecauer M, Bosshard G, Dojcinovic D, Baumgaertner P, Luescher IF. Soluble MHC-peptide complexes containing long rigid linkers abolish CTL-mediated cytotoxicity. J Immunol. 2006;176(6):3356-65. (Pubitemid 43363982)
53. Vincent BG, Young EF, Buntzman AS, Stevens R, Kepler TB, Tisch RM, Frelinger JA, Hess PR. Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice. J Immunol. 2010;184(8):4196-204.
54. Penaloza-MacMaster P, Masopust D, Ahmed R. T-cell reconstitution without T-cell immunopathology in two models of T-cell-mediated tissue destruction. Immunology. 2009;128(2):164-71.
55. Tsai S, Shameli A, Yamanouchi J, Clemente-Casares X, Wang J, Serra P, Yang Y, Medarova Z, Moore A, Santamaria P. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity. 2010;32(4):568-80.